Publications in collaboration with researchers from Complexo Hospitalario Universitario de Santiago (11)

2024

  1. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

2023

  1. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

    Hepatology, Vol. 77, Núm. 4, pp. 1095-1105

  2. The impact of obesity on postoperative complications and short-term survival after liver transplantation

    European Journal of Gastroenterology and Hepatology, Vol. 35, Núm. 7, pp. 782-789

2022

  1. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349

  2. Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study

    Liver Transplantation, Vol. 28, Núm. 7, pp. 1257-1261

2021

  1. Retrieval and treatment of patients with primary biliary cholangitis who are lost in the health system

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 113, Núm. 11, pp. 776-779

2020

  1. Ribavirin as a first treatment approach for hepatitis e virus infection in transplant recipient patients

    Microorganisms, Vol. 8, Núm. 1

2016

  1. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)

    Antiviral Therapy, Vol. 21, Núm. 3, pp. 195-205

2013

  1. Cholangitis and multiple liver abscesses after percutaneous ethanol injection (PEI) for recurrent hepatocellular carcinoma (HCC)

    Revista Espanola de Enfermedades Digestivas

2012

  1. Basiliximab en el tratamiento del rechazo celular agudo resistente a los corticoides postrasplante hepático

    Gastroenterologia y Hepatologia, Vol. 35, Núm. 9, pp. 649-651

  2. Indicaciones actuales de tratamiento triple para la hepatitis C

    Gastroenterologia y Hepatologia, Vol. 35, Núm. 4, pp. 266-277